(Source: Actelion Ltd) ALLSCHWIL/BASEL, SWITZERLAND - 16 February 2015- Actelion Ltd (SIX: ATLN) today announced its results for the full year 2014. OPERATING HIGHLIGHTS Opsumit - Sales of CHF 180 million reflect highly successful first year on the market Selexipag (Uptravi) - positive morbidity/mortality Phase III pivotal study results Selexipag (Uptravi) - Registration dossier submitted to US and European regulators Tracleer - Continued strong demand in markets where Opsumit is not yet available Tracleer - PIP Compliance Statement for Tracleer issued in Europe Veletri - Growing 84% (at CER) versus 2013 - becoming a global asset FINANCIAL HIGHLIGHTS Product sales of CHF 1,956 million,...
↧